Skip to main content
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases 2/2013

01.02.2013 | Article

Prevalence and molecular epidemiology of acquired AmpC β-lactamases and carbapenemases in Enterobacteriaceae isolates from 35 hospitals in Spain

verfasst von: E. Miró, J. Agüero, M. N. Larrosa, A. Fernández, M. C. Conejo, G. Bou, J. J. González-López, N. Lara, L. Martínez-Martínez, A. Oliver, B. Aracil, J. Oteo, A. Pascual, J. Rodríguez-Baño, L. Zamorano, F. Navarro

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

The purpose of this investigation was to determine the prevalence of plasmid-mediated AmpC (pAmpC) and carbapenemases in Enterobacteriaceae collected from 35 hospitals in Spain and to establish their epidemiological relationships. We conducted a prospective multi-centre study on pAmpC- or carbapenemase-producing Enterobacteriaceae isolates from clinical samples collected from February to July 2009. The strains suspected to carry pAmpC were resistant or showed intermediate susceptibility to co-amoxiclav and second- or third-generation cephalosporins. Strains suspected to carry a carbapenemase were selected because they showed a minimum inhibitory concentration (MIC) to imipenem >1 mg/L. Polymerase chain reaction (PCR) and a sequencing strategy were used to characterise the enzymes. The clonal relationships between isolates was analysed by pulsed field gel electrophoresis (PFGE). Among 100,132 Enterobacteriaceae isolates collected, 1,654 were compatible with the production of pAmpC or carbapenemases. We found a prevalence of 0.64 % of pAmpC (n = 635) and 0.04 % of carbapenemases (n = 43). The most prevalent pAmpC enzymes were CMY-type (78.3 %), DHA-type (19.5 %), ACC-type (1.6 %) and FOX-type (0.6 %). The CMY-type was the most frequent in Escherichia coli and Proteus mirabilis species, whereas the DHA-type was mainly found in Klebsiella spp. The enzymes involved in carbapenem resistance were VIM-1, IMP-22 and the new IMP-28. Nine new bla genes were described: bla CMY-54, bla CMY-55, bla CMY-56, bla CMY-57, bla CMY-96, bla DHA-6, bla DHA-7, bla FOX-8 and bla IMP-28. The prevalence of pAmpC or carbapenemases found is not negligible. The CMY-types were the predominant pAmpC, whereas the VIM or IMP enzymes were the predominant carbapenemases. Furthermore, we observed a great genetic diversity among pAmpC-producing strains and a close clonal relationship between carbapenemase-producing strains.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Pérez-Pérez FJ, Hanson ND (2002) Detection of plasmid-mediated AmpC β-lactamase genes in clinical isolates by using multiplex PCR. J Clin Microbiol 40:2153–2162PubMedCrossRef Pérez-Pérez FJ, Hanson ND (2002) Detection of plasmid-mediated AmpC β-lactamase genes in clinical isolates by using multiplex PCR. J Clin Microbiol 40:2153–2162PubMedCrossRef
2.
Zurück zum Zitat Mata C, Miró E, Rivera A et al (2010) Prevalence of acquired AmpC β-lactamases in Enterobacteriaceae lacking inducible chromosomal ampC genes at a Spanish hospital from 1999 to 2007. Clin Microbiol Infect 16:472–476PubMedCrossRef Mata C, Miró E, Rivera A et al (2010) Prevalence of acquired AmpC β-lactamases in Enterobacteriaceae lacking inducible chromosomal ampC genes at a Spanish hospital from 1999 to 2007. Clin Microbiol Infect 16:472–476PubMedCrossRef
3.
Zurück zum Zitat Navarro F, Pérez-Trallero E, Marimón JM et al (2001) CMY-2-producing Salmonella enterica, Klebsiella pneumoniae, Klebsiella oxytoca, Proteus mirabilis and Escherichia coli strains isolated in Spain (October 1999–December 2000). J Antimicrob Chemother 48:383–389PubMedCrossRef Navarro F, Pérez-Trallero E, Marimón JM et al (2001) CMY-2-producing Salmonella enterica, Klebsiella pneumoniae, Klebsiella oxytoca, Proteus mirabilis and Escherichia coli strains isolated in Spain (October 1999–December 2000). J Antimicrob Chemother 48:383–389PubMedCrossRef
4.
Zurück zum Zitat Yamasaki K, Komatsu M, Abe N et al (2010) Laboratory surveillance for prospective plasmid-mediated AmpC β-lactamases in the Kinki region of Japan. J Clin Microbiol 48:3267–3273PubMedCrossRef Yamasaki K, Komatsu M, Abe N et al (2010) Laboratory surveillance for prospective plasmid-mediated AmpC β-lactamases in the Kinki region of Japan. J Clin Microbiol 48:3267–3273PubMedCrossRef
5.
Zurück zum Zitat Song W, Kim JS, Kim HS et al (2006) Increasing trend in the prevalence of plasmid-mediated AmpC β-lactamases in Enterobacteriaceae lacking chromosomal ampC gene at a Korean university hospital from 2002 to 2004. Diagn Microbiol Infect Dis 55:219–224PubMedCrossRef Song W, Kim JS, Kim HS et al (2006) Increasing trend in the prevalence of plasmid-mediated AmpC β-lactamases in Enterobacteriaceae lacking chromosomal ampC gene at a Korean university hospital from 2002 to 2004. Diagn Microbiol Infect Dis 55:219–224PubMedCrossRef
6.
Zurück zum Zitat Empel J, Baraniak A, Literacka E et al (2008) Molecular survey of β-lactamases conferring resistance to newer β-lactams in Enterobacteriaceae isolates from Polish hospitals. Antimicrob Agents Chemother 52:2449–2454PubMedCrossRef Empel J, Baraniak A, Literacka E et al (2008) Molecular survey of β-lactamases conferring resistance to newer β-lactams in Enterobacteriaceae isolates from Polish hospitals. Antimicrob Agents Chemother 52:2449–2454PubMedCrossRef
7.
Zurück zum Zitat Miró E, Segura C, Navarro F et al (2010) Spread of plasmids containing the bla VIM-1 and bla CTX-M genes and the qnr determinant in Enterobacter cloacae, Klebsiella pneumoniae and Klebsiella oxytoca isolates. J Antimicrob Chemother 65:661–665PubMedCrossRef Miró E, Segura C, Navarro F et al (2010) Spread of plasmids containing the bla VIM-1 and bla CTX-M genes and the qnr determinant in Enterobacter cloacae, Klebsiella pneumoniae and Klebsiella oxytoca isolates. J Antimicrob Chemother 65:661–665PubMedCrossRef
8.
Zurück zum Zitat Oteo J, Hernández-Almaraz JL, Gil-Antón J et al (2010) Outbreak of VIM-1-carbapenemase-producing Enterobacter cloacae in a pediatric intensive care unit. Pediatr Infect Dis J 29:1144–1146PubMedCrossRef Oteo J, Hernández-Almaraz JL, Gil-Antón J et al (2010) Outbreak of VIM-1-carbapenemase-producing Enterobacter cloacae in a pediatric intensive care unit. Pediatr Infect Dis J 29:1144–1146PubMedCrossRef
9.
Zurück zum Zitat Conejo MC, Domínguez MC, López-Cerero L et al (2010) Isolation of multidrug-resistant Klebsiella oxytoca carrying bla IMP-8, associated with OXY hyperproduction, in the intensive care unit of a community hospital in Spain. J Antimicrob Chemother 65:1071–1073PubMedCrossRef Conejo MC, Domínguez MC, López-Cerero L et al (2010) Isolation of multidrug-resistant Klebsiella oxytoca carrying bla IMP-8, associated with OXY hyperproduction, in the intensive care unit of a community hospital in Spain. J Antimicrob Chemother 65:1071–1073PubMedCrossRef
10.
Zurück zum Zitat Giakoupi P, Maltezou H, Polemis M et al; Greek System for the Surveillance of Antimicrobial Resistance (2009) KPC-2-producing Klebsiella pneumoniae infections in Greek hospitals are mainly due to a hyperepidemic clone. Euro Surveill 14. pii: 19218 Giakoupi P, Maltezou H, Polemis M et al; Greek System for the Surveillance of Antimicrobial Resistance (2009) KPC-2-producing Klebsiella pneumoniae infections in Greek hospitals are mainly due to a hyperepidemic clone. Euro Surveill 14. pii: 19218
11.
Zurück zum Zitat Cuzon G, Ouanich J, Gondret R et al (2011) Outbreak of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in France. Antimicrob Agents Chemother 55:2420–2423PubMedCrossRef Cuzon G, Ouanich J, Gondret R et al (2011) Outbreak of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in France. Antimicrob Agents Chemother 55:2420–2423PubMedCrossRef
12.
Zurück zum Zitat Struelens MJ, Monnet DL, Magiorakos AP et al; European NDM-1 Survey Participants (2010) New Delhi metallo-β-lactamase 1-producing Enterobacteriaceae: emergence and response in Europe. Euro Surveill 15. pii: 19716 Struelens MJ, Monnet DL, Magiorakos AP et al; European NDM-1 Survey Participants (2010) New Delhi metallo-β-lactamase 1-producing Enterobacteriaceae: emergence and response in Europe. Euro Surveill 15. pii: 19716
13.
Zurück zum Zitat Miriagou V, Cornaglia G, Edelstein M et al (2010) Acquired carbapenemases in Gram-negative bacterial pathogens: detection and surveillance issues. Clin Microbiol Infect 16:112–22PubMedCrossRef Miriagou V, Cornaglia G, Edelstein M et al (2010) Acquired carbapenemases in Gram-negative bacterial pathogens: detection and surveillance issues. Clin Microbiol Infect 16:112–22PubMedCrossRef
14.
Zurück zum Zitat Navarro F, Calvo J, Cantón R et al (2011) Detection of resistance phenotypes in gram-negative bacteria. Enferm Infecc Microbiol Clin 29:524–534PubMedCrossRef Navarro F, Calvo J, Cantón R et al (2011) Detection of resistance phenotypes in gram-negative bacteria. Enferm Infecc Microbiol Clin 29:524–534PubMedCrossRef
15.
Zurück zum Zitat Walther-Rasmussen J, Høiby N (2007) Class A carbapenemases. J Antimicrob Chemother 60:470–482PubMedCrossRef Walther-Rasmussen J, Høiby N (2007) Class A carbapenemases. J Antimicrob Chemother 60:470–482PubMedCrossRef
16.
Zurück zum Zitat Clinical and Laboratory Standards Institute (CLSI) (2005) Performance standards for antimicrobial susceptibility testing; fourteenth informational supplement, M100-S14. CLSI, Wayne, PA, USA Clinical and Laboratory Standards Institute (CLSI) (2005) Performance standards for antimicrobial susceptibility testing; fourteenth informational supplement, M100-S14. CLSI, Wayne, PA, USA
17.
Zurück zum Zitat Pasteran F, Mendez T, Guerriero L et al (2009) Sensitive screening tests for suspected class A carbapenemase production in species of Enterobacteriaceae. J Clin Microbiol 47:1631–1639PubMedCrossRef Pasteran F, Mendez T, Guerriero L et al (2009) Sensitive screening tests for suspected class A carbapenemase production in species of Enterobacteriaceae. J Clin Microbiol 47:1631–1639PubMedCrossRef
18.
Zurück zum Zitat Dubois V, Poirel L, Marie C et al (2002) Molecular characterization of a novel class 1 integron containing bla GES-1 and a fused product of aac(3)-Ib/aac(6″)-Ib” gene cassettes in Pseudomonas aeruginosa. Antimicrob Agents Chemother 46:638–645PubMedCrossRef Dubois V, Poirel L, Marie C et al (2002) Molecular characterization of a novel class 1 integron containing bla GES-1 and a fused product of aac(3)-Ib/aac(6)-Ib” gene cassettes in Pseudomonas aeruginosa. Antimicrob Agents Chemother 46:638–645PubMedCrossRef
19.
Zurück zum Zitat Yigit H, Queenan AM, Anderson GJ et al (2001) Novel carbapenem-hydrolyzing β-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 45:1151–1161PubMedCrossRef Yigit H, Queenan AM, Anderson GJ et al (2001) Novel carbapenem-hydrolyzing β-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 45:1151–1161PubMedCrossRef
20.
Zurück zum Zitat Poirel L, Magalhaes M, Lopes M et al (2004) Molecular analysis of metallo-β-lactamase gene bla SPM-1-surrounding sequences from disseminated Pseudomonas aeruginosa isolates in Recife, Brazil. Antimicrob Agents Chemother 48:1406–1409PubMedCrossRef Poirel L, Magalhaes M, Lopes M et al (2004) Molecular analysis of metallo-β-lactamase gene bla SPM-1-surrounding sequences from disseminated Pseudomonas aeruginosa isolates in Recife, Brazil. Antimicrob Agents Chemother 48:1406–1409PubMedCrossRef
21.
Zurück zum Zitat Poirel L, Lambert T, Türkoglü S et al (2001) Characterization of Class 1 integrons from Pseudomonas aeruginosa that contain the bla VIM-2 carbapenem-hydrolyzing β-lactamase gene and of two novel aminoglycoside resistance gene cassettes. Antimicrob Agents Chemother 45:546–552PubMedCrossRef Poirel L, Lambert T, Türkoglü S et al (2001) Characterization of Class 1 integrons from Pseudomonas aeruginosa that contain the bla VIM-2 carbapenem-hydrolyzing β-lactamase gene and of two novel aminoglycoside resistance gene cassettes. Antimicrob Agents Chemother 45:546–552PubMedCrossRef
22.
Zurück zum Zitat Rodríguez-Baño J, Miró E, Villar M et al (2012) Colonisation and infection due to Enterobacteriaceae producing plasmid-mediated AmpC β-lactamases. J Infect 64:176–183PubMedCrossRef Rodríguez-Baño J, Miró E, Villar M et al (2012) Colonisation and infection due to Enterobacteriaceae producing plasmid-mediated AmpC β-lactamases. J Infect 64:176–183PubMedCrossRef
23.
Zurück zum Zitat Oteo J, Navarro C, Cercenado E et al (2006) Spread of Escherichia coli strains with high-level cefotaxime and ceftazidime resistance between the community, long-term care facilities, and hospital institutions. J Clin Microbiol 44:2359–2366PubMedCrossRef Oteo J, Navarro C, Cercenado E et al (2006) Spread of Escherichia coli strains with high-level cefotaxime and ceftazidime resistance between the community, long-term care facilities, and hospital institutions. J Clin Microbiol 44:2359–2366PubMedCrossRef
24.
Zurück zum Zitat Sabbuba NA, Mahenthiralingam E, Stickler DJ (2003) Molecular epidemiology of Proteus mirabilis infections of the catheterized urinary tract. J Clin Microbiol 41:4961–4965PubMedCrossRef Sabbuba NA, Mahenthiralingam E, Stickler DJ (2003) Molecular epidemiology of Proteus mirabilis infections of the catheterized urinary tract. J Clin Microbiol 41:4961–4965PubMedCrossRef
25.
Zurück zum Zitat Tenover FC, Arbeit RD, Goering RV et al (1995) Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 33:2233–2239PubMed Tenover FC, Arbeit RD, Goering RV et al (1995) Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 33:2233–2239PubMed
26.
Zurück zum Zitat Ding H, Yang Y, Lu Q et al (2008) The prevalence of plasmid-mediated AmpC β-lactamases among clinical isolates of Escherichia coli and Klebsiella pneumoniae from five children’s hospitals in China. Eur J Clin Microbiol Infect Dis 27:915–921PubMedCrossRef Ding H, Yang Y, Lu Q et al (2008) The prevalence of plasmid-mediated AmpC β-lactamases among clinical isolates of Escherichia coli and Klebsiella pneumoniae from five children’s hospitals in China. Eur J Clin Microbiol Infect Dis 27:915–921PubMedCrossRef
27.
Zurück zum Zitat Queenan AM, Bush K (2007) Carbapenemases: the versatile β-lactamases. Clin Microbiol Rev 20:440–458PubMedCrossRef Queenan AM, Bush K (2007) Carbapenemases: the versatile β-lactamases. Clin Microbiol Rev 20:440–458PubMedCrossRef
28.
Zurück zum Zitat Tórtola MT, Lavilla S, Miró E et al (2005) First detection of a carbapenem-hydrolyzing metalloenzyme in two Enterobacteriaceae isolates in Spain. Antimicrob Agents Chemother 49:3492–3494PubMedCrossRef Tórtola MT, Lavilla S, Miró E et al (2005) First detection of a carbapenem-hydrolyzing metalloenzyme in two Enterobacteriaceae isolates in Spain. Antimicrob Agents Chemother 49:3492–3494PubMedCrossRef
29.
Zurück zum Zitat Tato M, Coque TM, Ruíz-Garbajosa P et al (2007) Complex clonal and plasmid epidemiology in the first outbreak of Enterobacteriaceae infection involving VIM-1 metallo-β-lactamase in Spain: toward endemicity? Clin Infect Dis 45:1171–1178PubMedCrossRef Tato M, Coque TM, Ruíz-Garbajosa P et al (2007) Complex clonal and plasmid epidemiology in the first outbreak of Enterobacteriaceae infection involving VIM-1 metallo-β-lactamase in Spain: toward endemicity? Clin Infect Dis 45:1171–1178PubMedCrossRef
30.
Zurück zum Zitat Pérez-Llarena FJ, Fernández A, Zamorano L et al (2012) Characterization of a novel IMP-28 metallo-β-lactamase from a Spanish Klebsiella oxytoca clinical isolate. Antimicrob Agents Chemother 56:4540–4543PubMedCrossRef Pérez-Llarena FJ, Fernández A, Zamorano L et al (2012) Characterization of a novel IMP-28 metallo-β-lactamase from a Spanish Klebsiella oxytoca clinical isolate. Antimicrob Agents Chemother 56:4540–4543PubMedCrossRef
31.
Zurück zum Zitat Gaibani P, Ambretti S, Berlingeri A et al (2011) Rapid increase of carbapenemase-producing Klebsiella pneumoniae strains in a large italian hospital: surveillance period 1 March–30 September 2010. Euro Surveill 16. pii: 19800 Gaibani P, Ambretti S, Berlingeri A et al (2011) Rapid increase of carbapenemase-producing Klebsiella pneumoniae strains in a large italian hospital: surveillance period 1 March–30 September 2010. Euro Surveill 16. pii: 19800
32.
Zurück zum Zitat Solé M, Pitart C, Roca I et al (2011) First description of an Escherichia coli strain producing NDM-1 carbapenemase in Spain. Antimicrob Agents Chemother 55:4402–4404PubMedCrossRef Solé M, Pitart C, Roca I et al (2011) First description of an Escherichia coli strain producing NDM-1 carbapenemase in Spain. Antimicrob Agents Chemother 55:4402–4404PubMedCrossRef
33.
Zurück zum Zitat Pitart C, Solé M, Roca I et al (2011) First outbreak of a plasmid-mediated carbapenem-hydrolyzing OXA-48 β-lactamase in Klebsiella pneumoniae in Spain. Antimicrob Agents Chemother 55:4398–4401PubMedCrossRef Pitart C, Solé M, Roca I et al (2011) First outbreak of a plasmid-mediated carbapenem-hydrolyzing OXA-48 β-lactamase in Klebsiella pneumoniae in Spain. Antimicrob Agents Chemother 55:4398–4401PubMedCrossRef
34.
Zurück zum Zitat Oteo J, Cercenado E, Cuevas O et al (2010) AmpC β-lactamases in Escherichia coli: emergence of CMY-2-producing virulent phylogroup D isolates belonging mainly to STs 57, 115, 354, 393, and 420, and phylogroup B2 isolates belonging to the international clone O25b-ST131. Diagn Microbiol Infect Dis 67:270–276PubMedCrossRef Oteo J, Cercenado E, Cuevas O et al (2010) AmpC β-lactamases in Escherichia coli: emergence of CMY-2-producing virulent phylogroup D isolates belonging mainly to STs 57, 115, 354, 393, and 420, and phylogroup B2 isolates belonging to the international clone O25b-ST131. Diagn Microbiol Infect Dis 67:270–276PubMedCrossRef
35.
Zurück zum Zitat Naseer U, Haldorsen B, Simonsen GS et al (2010) Sporadic occurrence of CMY-2-producing multidrug-resistant Escherichia coli of ST-complexes 38 and 448, and ST131 in Norway. Clin Microbiol Infect 16:171–178PubMedCrossRef Naseer U, Haldorsen B, Simonsen GS et al (2010) Sporadic occurrence of CMY-2-producing multidrug-resistant Escherichia coli of ST-complexes 38 and 448, and ST131 in Norway. Clin Microbiol Infect 16:171–178PubMedCrossRef
36.
Zurück zum Zitat Empel J, Hrabák J, Kozińska A et al (2010) DHA-1-producing Klebsiella pneumoniae in a teaching hospital in the Czech Republic. Microb Drug Resist 16:291–295PubMedCrossRef Empel J, Hrabák J, Kozińska A et al (2010) DHA-1-producing Klebsiella pneumoniae in a teaching hospital in the Czech Republic. Microb Drug Resist 16:291–295PubMedCrossRef
37.
Zurück zum Zitat Ohana S, Leflon V, Ronco E et al (2005) Spread of a Klebsiella pneumoniae strain producing a plasmid-mediated ACC-1 AmpC β-lactamase in a teaching hospital admitting disabled patients. Antimicrob Agents Chemother 49:2095–2097PubMedCrossRef Ohana S, Leflon V, Ronco E et al (2005) Spread of a Klebsiella pneumoniae strain producing a plasmid-mediated ACC-1 AmpC β-lactamase in a teaching hospital admitting disabled patients. Antimicrob Agents Chemother 49:2095–2097PubMedCrossRef
38.
Zurück zum Zitat Psichogiou M, Tassios PT, Avlamis A et al (2008) Ongoing epidemic of bla VIM-1-positive Klebsiella pneumoniae in Athens, Greece: a prospective survey. J Antimicrob Chemother 61:59–63PubMedCrossRef Psichogiou M, Tassios PT, Avlamis A et al (2008) Ongoing epidemic of bla VIM-1-positive Klebsiella pneumoniae in Athens, Greece: a prospective survey. J Antimicrob Chemother 61:59–63PubMedCrossRef
39.
Zurück zum Zitat Cagnacci S, Gualco L, Roveta S et al (2008) Bloodstream infections caused by multidrug-resistant Klebsiella pneumoniae producing the carbapenem-hydrolysing VIM-1 metallo-β-lactamase: first Italian outbreak. J Antimicrob Chemother 61:296–300PubMedCrossRef Cagnacci S, Gualco L, Roveta S et al (2008) Bloodstream infections caused by multidrug-resistant Klebsiella pneumoniae producing the carbapenem-hydrolysing VIM-1 metallo-β-lactamase: first Italian outbreak. J Antimicrob Chemother 61:296–300PubMedCrossRef
Metadaten
Titel
Prevalence and molecular epidemiology of acquired AmpC β-lactamases and carbapenemases in Enterobacteriaceae isolates from 35 hospitals in Spain
verfasst von
E. Miró
J. Agüero
M. N. Larrosa
A. Fernández
M. C. Conejo
G. Bou
J. J. González-López
N. Lara
L. Martínez-Martínez
A. Oliver
B. Aracil
J. Oteo
A. Pascual
J. Rodríguez-Baño
L. Zamorano
F. Navarro
Publikationsdatum
01.02.2013
Verlag
Springer-Verlag
Erschienen in
European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 2/2013
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-012-1737-0

Weitere Artikel der Ausgabe 2/2013

European Journal of Clinical Microbiology & Infectious Diseases 2/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

NSCLC: Progressionsfreies Überleben unter Osimertinib fast versiebenfacht

06.06.2024 ASCO 2024 Kongressbericht

Erste Ergebnisse der Phase-III-Studie LAURA etablieren Osimertinib als neuen Therapiestandard für Menschen mit nicht-resezierbarem, EGFR-mutiertem, nicht-kleinzelligem Lungenkarzinom im Stadium III, die nach definitiver Radiochemotherapie progressionsfrei sind. Auf der ASCO-Tagung wurden diese beeindruckenden Ergebnisse besprochen.

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gute molekulare Response, aber seltener ernste Nebenwirkungen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.